Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 17 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. METHODS: We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change in the apnea-hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline. Key multiplicity-controlled secondary end points included the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure. RESULTS: At baseline, the mean AHI was 51.5 events per hour in trial 1 and 49.5 events per hour in trial 2, and the mean body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) was 39.1 and 38.7, respectively. In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2) (P<0.001). In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9) (P<0.001). Significant improvements in the measurements for all prespecified key secondary end points were observed with tirzepatide as compared with placebo. The most frequently reported adverse events with tirzepatide were gastrointestinal in nature and mostly mild to moderate in severity. CONCLUSIONS: Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004.).
Overview
CoChat Summary
## TL;DR
In two 52-week phase 3 randomized controlled trials of adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide improved apnea-hypopnea index (AHI) and multiple secondary outcomes versus placebo. The paper concludes that tirzepatide reduced sleep-disordered breathing, body weight, hypoxic burden, hsCRP, systolic blood pressure, and improved sleep-related patient-reported outcomes.
## Key findings
- In trial 1, the mean change in AHI at week 52 was -25.3 events/hour with tirzepatide versus -5.3 events/hour with placebo; the estimated treatment difference was -20.0 events/hour (95% CI, -25.8 to -14.2; P<0.001).
- In trial 2, the mean change in AHI at week 52 was -29.3 events/hour with tirzepatide versus -5.5 events/hour with placebo; the estimated treatment difference was -23.8 events/hour (95% CI, -29.6 to -17.9; P<0.001).
- In the pooled analysis, participants receiving tirzepatide had significant reductions in PROMIS-SRI and PROMIS-SD T scores, and both trials showed significant reductions in body weight, systolic blood pressure, and hsCRP concentrations.
- The paper states that the most frequently reported adverse events with tirzepatide were gastrointestinal and generally mild-to-moderate; adverse events occurred in 79.8% vs 76.7% of participants in trial 1 and 83.2% vs 72.8% in trial 2 (tirzepatide vs placebo).
## Methods
- Two 52-week, phase 3, multicenter, parallel-group, double-blind, randomized, controlled trials were conducted at 60 sites across nine countries.
- Adults with moderate-to-severe obstructive sleep apnea (AHI ≥15 events/hour) and obesity (BMI ≥30; ≥27 in Japan) were enrolled; trial 1 included participants unable or unwilling to use PAP, and trial 2 included participants using PAP for at least 3 consecutive months and planning to continue.
- Participants were randomized 1:1 to weekly tirzepatide (10 mg or 15 mg maximum tolerated dose) or placebo; the primary endpoint was change in AHI from baseline, with key secondary endpoints including AHI percent change, body weight, hypoxic burden, hsCRP, patient-reported sleep outcomes, and systolic blood pressure. Analyses used ANCOVA and logistic regression, with multiplicity control via a graphical testing procedure.
## Limitations
- The paper states that the shorter duration of the trials does not support assessment of long-term cardiovascular outcomes.
- The trials excluded participants without obesity and did not assess people with overweight or normal BMI.
- The trials were not designed to test whether results differed by baseline symptoms, and trial 2 was not designed to assess PAP adherence effects; also, the minimum clinically important changes for PROMIS-SRI and PROMIS-SD were not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 0 Not valid · 6 Not checked · 57 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Excess adiposity is a major reversible etiologic risk factor for obstructive sleep apnea and its complications. 8,9”
What the sources say
- Supportedcites [8] 8. Hudgel DW, Patel SR, Ahasic AM, et al. The role of weight management in the treatment of adult obstructive sleep apnea: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2018;198(6):e70-e87. [PubMed: 30215551] source
The Introduction says weight gain is linked to the development and worsening of OSA and that obesity aggravates its metabolic and cardiovascular comorbidities. “Putting It All Together” reports that weight loss consistently improves OSA severity and may improve associated health outcomes, supporting reversibility. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [9] 9. Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006;29:1031-5. [PubMed: 16944671] source
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This level of weight reduction has been difficult to accomplish with lifestyle intervention alone. 35”
What the sources say
- Partly supportedcites [35] 35. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014;348:g2646. [PubMed: 25134100] sourceExperimental — accuracy not yet measured
The Introduction says few people maintain weight loss over the long term, and the Behavioural/lifestyle v control section reports a modest mean difference of −1.56 kg at 12 months. This supports the general difficulty of sustaining weight loss with lifestyle intervention, but the claim does not specify what “this level” is, so the paper cannot verify that particular level. (LLM, conf=0.78)
- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The potential issue of PAP confounding of the PROMIS outcomes in trial 2 was minimized by a 7-day PAP washout period. 22”
What the sources say
- Partly supportedcites [22] 22. Schwarz EI, Stradling JR, Kohler M. Physiological consequences of CPAP therapy withdrawal in patients with obstructive sleep apnoea-an opportunity for an efficient experimental model. J Thorac Dis 2018;10:Suppl 1:S24-S32. [PubMed: 29445525] sourceExperimental — accuracy not yet measured
The Physiological effects of CPAP withdrawal section reports that OSA recurred and subjective sleepiness increased one week after CPAP withdrawal, supporting the rationale for a washout. It does not assess PROMIS outcomes or establish that seven days minimized PAP confounding in trial 2; sleepiness continued to increase at two weeks. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile of tirzepatide was consistent with that observed in previous trials. 14,3739”
What the sources say
- Not checked — no full text of the sourcecites [14] 14. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16. [PubMed: 35658024] source
- Supportedcites [37] 37. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2023;402:613-26. [PubMed: 37385275] source
The Discussion explicitly states that tirzepatide’s safety profile was consistent with previous findings in the SURMOUNT-1 and SURPASS trials. The Safety section also describes the adverse events observed in this trial. (LLM, conf=0.95)
- Supportedcites [38] 38. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29:2909-18. [PubMed: 37840095] source
The Discussion explicitly states that tirzepatide’s safety profile in this trial was consistent with findings from previous tirzepatide trials. It also notes modestly higher rates of gastrointestinal adverse events and treatment discontinuation than in the tirzepatide 15 mg group in SURMOUNT-1; that qualification does not negate the overall comparison. (LLM, conf=0.95)
- Partly supportedcites [39] 39. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. [PubMed: 38078870] sourceExperimental — accuracy not yet measured
The Results (Adverse Events and Tolerability; page unavailable) describe tirzepatide’s safety findings, including gastrointestinal events and serious adverse events. The passages do not compare that safety profile with previous trials, so the claimed consistency with earlier findings is not established by our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were five cases of severe or serious depressive disorder or suicidal ideation or behavior events across both trials (two with tirzepatide and three with placebo).”
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
29 more claims
Create a free account to see all 77 claims and every source verdict.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 31
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, some studies were designed for other purposes17,18,30,41–44—for example, prevention of CVD or T2D.”
From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [43]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SURMOUNT-OSA trial reported that tirzepatide reduced the apnea-hypopnea index by 25% to 29% over 52 weeks in individuals with obesity and moderate to severe OSA, compared with a reduction of 5.3% to 5.5% in the placebo group, regardless of the use of positive airway pressure therapy (19).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Benjafield, A. V., Ayas, N. T., Eastwood, P. R., Heinzer, R., Ip, M. S. M., Morrell, M. J., Nunez, C. M., Patel, S. R., Penzel, T., Pépin, J.-L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30198-5 · Cited by 4,326
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationAdult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine, Epstein, L. J., Kristo, D., Strollo, P. J., Friedman, N., Malhotra, A., Patil, S. P., Ramar, K., Rogers, R., Schwab, R. J., et al. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27497 · Cited by 3,360
Self-citationCPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
McEvoy, R. D., Antic, N. A., Heeley, E., Luo, Y., Ou, Q., Zhang, X., Mediano, O., Chen, R., Drager, L. F., Liu, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606599 · Cited by 2,101
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Adult obstructive sleep apnoea
Jordan, A. S., McSharry, D. G., & Malhotra, A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60734-5 · Cited by 1,735
Self-citationJavaheri, S., Barbe, F., Campos-Rodriguez, F., Dempsey, J. A., Khayat, R., Javaheri, S., Malhotra, A., Martinez-Garcia, M. A., Mehra, R., Pack, A. I., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.069 · Cited by 1,434
Self-citationYeghiazarians, Y., Jneid, H., Tietjens, J. R., Redline, S., Brown, D. L., El-Sherif, N., Mehra, R., Bozkurt, B., Ndumele, C. E., Somers, V. K., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000988 · Cited by 1,431
Self-citationRamar, K., Dort, L. C., Katz, S. G., Lettieri, C. J., Harrod, C. G., Thomas, S. M., & Chervin, R. D. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.4858 · Cited by 915
Azarbarzin, A., Sands, S. A., Stone, K. L., Taranto-Montemurro, L., Messineo, L., Terrill, P. I., Ancoli-Israel, S., Ensrud, K., Purcell, S., White, D. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy624 · Cited by 893
Self-citation
Cited by
Items 301–400 of 823
Leonhard, A. G., Josey, K., Castaneda, J. M., Chee, M., Duan, K. I., Nadeem, H., Plumley, R., Triplette, M., Smith, N. L., Au, D. H., et al. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag047 · Cited by 3
Management of Obesity in Psoriasis Consultations
Nicolau, J., López‐Ferrer, A., & de la Cueva, P. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01664-7 · Cited by 5
Incretins for obstructive sleep apnea: effects mediated fully by weight loss?
Peng, L., Chen, L., Lei, W., & Wen, W.-P. (2024) · SLEEP · doi:10.1093/sleep/zsae232 · Cited by 3
Molecular Biomarkers and Therapeutic Approach of Patients with Diabetes and Obstructive Sleep Apnea
Elian, V., Popovici, V., Steriade, A. T., Radulian, G., Ozon, E. A., Moroșan, E., & Muşat, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010234 · Cited by 6
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Sex Differences in Atherosclerotic Cardiovascular Disease Risk in Obstructive Sleep Apnea
Bock, J. M., Venkatesh, V., & Somers, V. K. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01311-0 · Cited by 2
The impact of sleep apnea on epilepsy treatment outcomes
Pavlova, M. K., Radmand, R., Lee, C. Y., Grom, J., Javaheri, S., & Daruvala, S. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2546866 · Cited by 6
Obstructive Sleep Apneas and Cardiovascular Diseases
Castiglione, V., Morfino, P., Fabiani, I., Gentile, F., Airò, E., Volpi, B., Cardinale, D. M., Passino, C., Giannoni, A., & Emdin, M. (2026) · Clocks & Sleep · doi:10.3390/clockssleep8020028 · Cited by 7
Redefining Obstructive Sleep Apnea: Treatment in the Modern Era
Redondo, J., Ascher, K. B., & Abreu, A. R. (2026) · Pathophysiology · doi:10.3390/pathophysiology33010020 · Cited by 4
OSA Endotyping as Targets for Treatment. How Far Have We Come?
McNicholas, W. T., de Beeck, S. O., Tondo, P., Verbraecken, J. A., & Bonsignore, M. R. (2026) · Respirology · doi:10.1002/resp.70233 · Cited by 3
Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity
Innocent, B., Elmaoued, A. A., Cowart, K., & White, R. T. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf088 · Cited by 5
Song, Z., Zhao, H., Yu, X., & Sun, X. (2026) · Medicine · doi:10.1097/md.0000000000047409 · Cited by 3
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 5
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Gabery, S., Glendorf, T., Ballarín-González, B., Pedersen, K., Kruse, T., Raun, K., & Kuhre, R. E. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123845 · Cited by 4
Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea
Noreña, J. A., Akcan, T., & Desai, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000949 · Cited by 3
Benefits of Supplementing a GLP-1 Type Medication With Physical Activity
Ablah, E. A., Imboden, M. T., Zendell, A. L., Hosking, M., Anderson, R. E., VanHoose, K., Peterson, N. E., Wojcik, J. R., Pronk, N. P., Harber, M., et al. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251357130 · Cited by 3
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Cardiovascular disease risk in people of African ancestry with HIV in the United Kingdom
Ko, S., Domínguez, L., Ottaway, Z. V., Campbell, L. J., Fox, J., Burns, F. M., Hamzah, L., Ustianowski, A., Clarke, A. E., Kegg, S., et al. (2024) · HIV Medicine · doi:10.1111/hiv.13706 · Cited by 1
Current clinical application of incretin therapy for obesity management
Skinner, K., & Clements, J. N. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0152 · Cited by 5
Tan, W., Deng, X., Tan, X., & Tan, G. (2024) · Medicine · doi:10.1097/md.0000000000040194 · Cited by 2
Chou, C. A., Khan, A., & Singh, A. (2025) · Sleep Science and Practice · doi:10.1186/s41606-025-00150-x · Cited by 2
Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients
Kutler, R. B., Lin, A., Zhang, L., Trackey, P., Rivera‐Diaz, A., Jelić, S., St‐Onge, M., & Cai, Y. (2026) · Otolaryngology · doi:10.1002/ohn.70231 · Cited by 2
Patient-reported preferences for sleep apnoea treatments in an Australian community sample
Stone, J., Joosten, S. A., Beatty, C., Collet, J., Thomson, L. D. J., Hamilton, G. S., Edwards, B. A., & Landry, S. A. (2025) · Sleep Health · doi:10.1016/j.sleh.2025.10.001 · Cited by 3
Obstructive Sleep Apnea and Type 2 Diabetes
LeBlanc, A. (2024) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2024.2227 · Cited by 2
Yang, Y.-T., Hou, X.-Z., Zhang, X.-R., Zhang, Z., & Wang, S.-H. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108671 · Cited by 2
Cardiovascular effects of semaglutide and tirzepatide and their potential for cardioprevention
Cherkashin, D. V., Салухов, В. В., & Khalimov, Y. S. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-323 · Cited by 2
Epicardial fat and sleep apnea: perspective mechanisms, diagnostics, and therapeutics
Varghese, R. T., Akurati, S., & Iacobellis, G. (2025) · Obesity and Endocrinology · doi:10.1093/obendo/wjaf009 · Cited by 6
Kushner, P. R., Campos, C., King, A., Kruger, D. F., & Morales, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0037 · Cited by 3
Medikamentöse Adipositastherapie in Deutschland
Blüher, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01897-2 · Cited by 4
Sleep and obesity—known interactions and open questions
Schmickl, C. N., Gomez, R., Sunwoo, B. Y., Mesarwi, O. A., Kumar, A., & Malhotra, A. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00130-7 · Cited by 3
Self-citationJennings, I., Ly, K., Marooki, M., Dzotsi, M., McLaren, G., Cuomo, R. E., Abohashem, S., & Taub, P. R. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag279 · Cited by 2
Estephan, L. E., White, S. F., Ideker, H. C., & Huntley, C. T. (2025) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-025-00524-w · Cited by 2
Schmickl, C. N., Tripipitsiriwat, A., Mokhlesi, B., et al. (2025) · medRxiv · doi:10.1101/2025.10.02.25337176 · Cited by 2
Grote, L., Gouveris, H. T., Lethuillier, L., Verbraecken, J. A., Başoğlu, Ö. K., Schiza, S. E., Ludka, O., Ryan, S., Joppa, P., Fanfulla, F., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00707-2025 · Cited by 3
Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity
Wu, J., Lin, Y., Hsu, W., Liu, T.-H., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoaf070 · Cited by 4
The Past and Future of Sleep Medicine
Kryger, M. H., & THOMAS, R. J. (2024) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2024.10.012 · Cited by 3
Dose–response relationship of sleep apnea therapy and healthcare use in patients with comorbidities
Malhotra, A., More, S., Alpert, N., Pépin, J., Cole, K. V., Woodford, C., Benjafield, A., Cistulli, P. A., Sterling, K. L., medXcloud Group, et al. (2025) · SLEEP · doi:10.1093/sleep/zsaf333 · Cited by 7
Self-citationObstructive Sleep Apnoea Treatments—Where Are We Now?
Luu, S., Lee, D., & Yee, B. J. (2025) · Respirology · doi:10.1111/resp.70109 · Cited by 3
Mehra, R., & Mokhlesi, B. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag243 · Cited by 2
Barenbaum, S. R., Aras, M., Kashyap, S. R., & Aronne, L. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf641 · Cited by 2
Randerath, W. J., Fanfulla, F., & Pépin, J. (2026) · European Respiratory Review · doi:10.1183/16000617.0260-2025 · Cited by 3
Gell, L. K., Bertisch, S. M., Lawrence, N. V., Gilbertson, D., Calianese, N. A., Messineo, L., Vena, D., Wang, T. Y., Bakker, J. P., Sofer, T., et al. (2026) · Thorax · doi:10.1136/thorax-2025-224467 · Cited by 2
Self-citationBariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
Stewart, K. D., Matza, L. S., Dunn, J. P., Neff, L. M., Niemeyer, A., Boye, K. S., & Shinde, S. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2572051 · Cited by 2
Self-citationKammaripalle, T. K. C., Giordano, J., Rana, H., Gade, A. R., & Reddy, S. (2025) · Cureus · doi:10.7759/cureus.85366 · Cited by 4
Targeting OSA endotypes with drug therapy: dream or reality?
Cistulli, P. A., & Mohammadieh, A. M. (2025) · Thorax · doi:10.1136/thorax-2025-223409 · Cited by 2
Assessing the Pathophysiology, Morbidity, and Mortality of Obstructive Sleep Apnea
Rc, R. (2024) · Journal of Insurance Medicine · doi:10.17849/insm-51-3-1-20.2 · Cited by 2
Arterburn, D. E., Curtis, L. H., Toh, S., Bradley, M. C., D’Alessio, D., Duchovny, N., Hines, D. W., Narain, K. D. C., Parekh, A., Skinner, A., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05468 · Cited by 3
Liu, L., Chen, J., Zhang, X., Zhu, S., Dai, T., Wu, Q., & Fang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02064-1 · Cited by 3
Sleep apnea and the ageing brain: Bridging mechanisms and clinical outcomes
Kosasih, A. M., Chong, Y. F. V., Lee, P., Zhou, J. H., Lim, D. C., & Lee, C. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.05.038 · Cited by 2
Tang, H., Zhang, B., Lu, Y., Zhang, D., Lu, Y., Asch, D. A., & Yong, C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.50978 · Cited by 3
Radbel, J. M., Brigham, E. P., Bayram, H., Rabin, A. S., Ewart, G. W., Rice, M., Cerceo, E. A., Mosesón, E. M., Baid, H., Trent, L., et al. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag055 · Cited by 4
Feng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 3
Heimann, A. S., Singh, P., Ferro, E. S., Greenway, F. L., & Krongrad, A. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70056 · Cited by 4
Perspective: Precision medicine in OSA: the future of a past and present riddle
Gonzalo Labarca, T. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11746 · Cited by 2
Courtney, L. A., Clements, J. N., Isaacs, D. M., Pitlick, J. M., Reece, S. W., & Whitley, H. P. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103314 · Cited by 3
GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
Gandhi, A., Phyu, E. M., Koom‐Dadzie, K., Dickson, K. B., & Halm, J. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062853 · Cited by 6
Update on clinical heart failure trials
Hoevelmann, J., Tokcan, M., Kulenthiran, S., Abdin, A., Viljoen, C. A., & Böhm, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02784-4 · Cited by 2
Infante, M., Ricordi, C., Pacifici, F., Pastore, D., Infante, R., Caprio, M., Chiereghin, F., Stefano, A. D., Frank, G., Rose, A. D., et al. (2026) · Nutrients · doi:10.3390/nu18132038 · Cited by 3
BORISSOV, M., Hwang, S. Y., Wickwire, E. M., & So, J. Y. (2026) · Sleep And Breathing · doi:10.1007/s11325-026-03748-2 · Cited by 2
Panou, T., Gouveri, E., Drakopanagiotakis, F., et al. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2567-7542 · Cited by 2
Somers, K. R., Becari, C., Polonis, K., & Singh, P. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102030 · Cited by 2
Patients’ Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study
Shinde, S., Kanu, C., Varnado, O. J., Bednařík, J., Dennehy, E. B., Dias-Barbosa, C., & Taylor, N. C. (2026) · Patient · doi:10.1007/s40271-026-00808-3 · Cited by 3
Giordano, S. A., Salval, A., Summa, P. G. D., & Oranges, C. M. (2025) · Surgeries · doi:10.3390/surgeries6020042 · Cited by 4
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 4
Three-Year Outcomes of Proximal Hypoglossal Nerve Stimulation in OSA
Schwartz, A. R., Jacobowitz, O., Mickelson, S. A., Miller, M. B., Oliven, A., Certal, V., Hopp, M. L., Winslow, D. H., Huntley, T. C., Nachlas, N. E., et al. (2026) · CHEST Journal · doi:10.1016/j.chest.2025.11.057 · Cited by 6
Self-citationAhmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
Heart failure with preserved ejection fraction: a systemic condition of comorbidities
Harrington, J., & Pandey, A. (2026) · Heart Failure Reviews · doi:10.1007/s10741-025-10586-z · Cited by 4
Glucagon‐Like Peptide‐1 Receptor Agonists in Obesity‐Induced Respiratory Pathophysiology
Ruiz, M. A., Furquim, T. H. D. C., Davaanyam, D., Williams, N. R., Polotsky, V. Y., & Amorim, M. R. (2026) · Acta Physiologica · doi:10.1111/apha.70171 · Cited by 3
Alfaris, N., Kushner, R. F., Li, J., Chen, K. L., Fenimore, M., Calderón, B., & Stefański, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70991 · Cited by 3
Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro–con debate
Patel, S. R., & Ryan, S. (2026) · European Respiratory Review · doi:10.1183/16000617.0255-2025 · Cited by 2
Diabetes and Obstructive Sleep Apnoea: Exploring the Bi-directional Link
Kantroo, V., Bhattacharya, S., Attri, B., Chopra, A., & Kalra, S. (2025) · Apollo Medicine · doi:10.1177/09760016251329043 · Cited by 2
Incretins for management of obesity and obstructive sleep apnea
Hu, X., Yee, B. J., Phillips, C. L., Chapman, J. L., & Grunstein, R. R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2513516 · Cited by 2
Self-citationWang, S., Fan, D., Yao, Q., & Sun, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16580 · Cited by 3
Alebna, P. L., Martey, S., Mehta, A., Lavie, C. J., & Carbone, S. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02333-5 · Cited by 3
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107184 · Cited by 1
Черкашин, Д. В. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-551 · Cited by 1
Prado, B. S., Mazzotti, D. R., Franci, A., Baracioli, L., Barbado, K. R., Saretta, R., Filho, R. K., & Drager, L. F. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoaf071 · Cited by 1
The year in cardiovascular medicine 2024: the top 10 papers in diabetes and metabolic disorders
Cosentino, F., Cannon, C. P., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf280 · Cited by 1
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Kato, S., Kokita, A., Akanuma, H., Iwamura, S., Takahashi, Y., Kusumi, R., Abe, S., Sasaki, K., Otomo, H., Ando, S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112913 · Cited by 3
A Brief History of COPD: As Told by Some of Its Senior Scientists and Clinicians
Nici, L. L., Celli, B. R., Mannino, D. M., Rennard, S., Agusti, A. A., Lareau, S. C., Meek, P., O'Donnell, D. E., Neder, J. A., Wedzicha, J. A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103914 · Cited by 3
Hawas, Y., Abouzid, M., Gadelmawla, A. F., Ewis, D. K., Khatatbeh, A. E., Negida, Y., & Negida, A. (2026) · Brain and Behavior · doi:10.1002/brb3.71702 · Cited by 2
Luo, D., Sun, J., Mo, B., Liu, T., Qin, J., Zhang, L., & Zhang, T. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108976 · Cited by 1
The impact of weight change on mortality and cardiovascular outcomes in obstructive sleep apnea
Liu, Y., Zhao, W., Zhou, Y., Zhang, Z., Li, S., Yan, Y., Ai, H., Nie, S., & Gong, W. (2025) · SLEEP · doi:10.1093/sleep/zsaf350 · Cited by 2
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Governor, S., Essien, E., Agyekum, A. K., Ahsan, A., Wiesel, S., Khurana, D., El‐Kersh, K., Altaee, O., Otchere, P., & Dávila‐Román, V. G. (2026) · medRxiv · doi:10.64898/2026.01.20.26344489 · Cited by 1
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
Thiriveedi, M., Domingo, F. S., Yates, H., Baddam, S., Beblawy, R. E., Nimmana, B., & Patel, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004055 · Cited by 7
Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity
Dong, S., Xu, Y., Gan, R., Zhang, A., He, J., & Tang, Q. (2026) · Medicinal Research Reviews · doi:10.1002/med.70049 · Cited by 1
Luca, M. D., Modestino, M. R., Alsergani, A. H., Gabriele, M., Galzerano, D., Mallardo, M., Saldamarco, L., Bossone, E., & Cittadini, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103328 · Cited by 4
Zwane, A., & Mpungose, S. (2025) · International Journal of Applied Research in Business and Management · doi:10.51137/wrp.ijarbm.352 · Cited by 1
Polotsky, V. Y., Kim, L. J., Taranto‐Montemurro, L., Yee, J., & Jun, J. C. (2026) · Current Pulmonology Reports · doi:10.1007/s13665-026-00405-7 · Cited by 2
Emerging Treatments for Obesity: the Role of GLP1 Receptor Agonists on Stroke
Mariscal, M., & Testai, F. D. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01423-9 · Cited by 2
Weekly Journal Scan: tirzepatide SURMOUNTs obesity-related obstructive sleep apnoea
Liuzzo, G., & Patrono, C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae568 · Cited by 1
Metadata
- Authors
- Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., & Bednarik, J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the University of California, San Diego, La Jolla (A.M.); Woolcock Institute of Medical Research, Macquarie University, Royal Prince Alfred Hospital, and the University of Sydney — all in Sydney (R.R.G.); the Center of Sleep Medicine, Charité University Hospital Berlin, Berlin (I.F.); the College of Nursing, University of Illinois Chicago, Chicago (T.E.W.); the School of Nursing (T.E.W.) and Perelman School of Medicine (R.J.S.), University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, and Harvard Medical School — both in Boston (S.R., A.A., S.A.S.); and Eli Lilly, Indianapolis (J.P.D., S.C., M.C.B., J.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-03
- Volume
- 391
- Issue
- 13
- Pages
- 1193-1205
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11598664
- OpenAlex
- W4399907994
- Cited by
- 871
- References
- 39
- Citations by year
- 2026: 410 · 2025: 379 · 2024: 80
- FWCI
- 245.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
- Keywords
- tirzepatide, obstructive sleep apnea, obesity, GLP-1 receptor agonists, GIP receptor agonist, apnea-hypopnea index, weight loss, positive airway pressure, hypoxic burden, sleep disorders, C-reactive protein, systolic blood pressure, cardiovascular risk, anti-obesity drugs, obesity-related sleep apnea, body mass index
- MeSH terms
- Sleep Quality, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Hypoxia, Blood Pressure, Body Weight, C-Reactive Protein, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Male, Middle Aged, Obesity, Severity of Illness Index, Treatment Outcome, Sleep Apnea, Obstructive, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.